This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are “material information” as defined in the Policies. The discussion in this report must be factual, balanced, and non-promotional.

General Instructions

1. Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered, nor should question be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title of each item must precede the answer.

2. The term “Issuer” includes the Issuer and any of its subsidiaries.

3. Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer continued its business of developing and accelerating the commercialization of its proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor, and assess cancer treatment early, accurately, and cost-effectively. The Company has developed its annual roadmap, continues to hold regular management meetings regarding all aspects of the Company’s business plan, and executes action items that result from these meetings.

Management’s primary areas of focus continue to include:

• Accelerating commercialization efforts of its lab-developed test (LDT) for early lung cancer detection following promising interim retrospective data presented at various oncology conferences across N. America and Europe.

• These results were statistically significant and continued to generate interest from leading institutions in the US, France, Germany and South America which the company intends to pursue post-launching its assay initially in Canada following certification of its Quebec-based lab and data readout on its lung cancer clinical studies.

• Complete data analytics on the large-scale early lung cancer multimodal study (5,400 patients) across 7 hospitals based in Quebec after the successful completion of plasma samples and analysis using BioMark’s metabolomics assay. Preliminary results on cancer confirmed (retrospective) cases are expected by early/mid 2025. Additional data on prospective lung cancer screening cohort will continue to be collected in 2025 as detailed in the clinical design. Pending the outcome of the results the company intends to present it a major cancer symposium.

• Preparation for lab certification and accreditation to initially meet international ISO 15189:2022 standard for the Canadian operation and later secure CLIA and CAP accreditation to provide lab services in the U.S. Canadian certification is expected by Q3 of 2025 following recent meetings with certification authorities. The lab team has diligently prepared all necessary documentation for registration, setting up data security infrastructure and is looking at hiring a Quality Systems Director.

• Seek deeper collaborations with several high-profile USA medical institutions and introduce the company to insurance companies (payers), regulatory experts, advocacy groups, and biopharma partners as its early lung cancer LDT commercialization efforts gather momentum. The US market is strategic due to its large addressable lung cancer screening market for at-risk populations (estimated at over 16 million annually). The market remains mostly untapped as there’s only a 5-6% penetration of image-based screening for the population at risk of developing lung cancer. In addition, the federal government is encouraging expanded accessibility for lung cancer screening initiatives across different states, especially for rural communities that are resource constrained.

• Continue to seek and secure the necessary funding to unlock the full potential of its diagnostic platform. The Company will continue to target non-dilutive funding opportunities from Canadian, European, and U.S. agencies and foundations to support key initiatives, including:

• • Optimizing our lab operations

  • Achieving clinical lab certification

  • Driving U.S. expansion

  • Fueling business development

  • Conducting clinical studies to extend the platform to additional cancers and define its role in treatment response assessment.

2. Provide a general overview and discussion of the activities of management.

• Political tensions with the new US administration and the potential imposition of tariffs continue to create anxiety and uncertainty across the business spectrum. The on and off deadlines pose uncertainty and difficulties in business planning.

Tariffs can have a complex and potentially significant impact on Canadian businesses, particularly small diagnostics companies like BioMark. Below is a breakdown of the key areas of concern:

• Increased Costs: Tariffs on imported goods increase the cost of raw materials, components, and finished products. This can lead to higher prices for consumers and businesses. For a diagnostics company, this could mean increased costs for laboratory equipment, reagents, and other essential supplies.

• Supply Chain Disruptions: Tariffs can disrupt established supply chains, leading to delays and shortages.

• Trade Uncertainty: Tariffs can create uncertainty in the marketplace, making it difficult for businesses to plan and invest. This uncertainty can discourage investment and hinder economic growth.

• Increased Operating Costs: Small companies often have limited resources and may struggle to absorb increased costs. This could impact BioMark’s ability to invest in research and development, which is crucial for innovation in the diagnostics industry.

• BioMark operates within a challenging economic environment that significantly impacts small-cap diagnostic companies. Rising interest rates have depressed investor risk sentiment in speculative sectors, resulting in biotech funding declining 43.2% in 2023 versus 2022 and 52.3% versus 2021. Extended financing timelines and selective investor behavior favor clinical-stage companies, creating additional hurdles for emerging diagnostic firms seeking funding or leasing arrangements. Concurrently, critical skilled labor shortages in bioinformatics and cybersecurity with a global gap of 4.8 million cybersecurity professional might directly impact on our ability to scale operations and maintain regulatory compliance essential for market entry.

• Government-funded collaborative programs with DoD, NIH, and other federal agencies face prolonged review processes and budget constraints, with 37% of organizations experiencing budget cuts in 2024. These macroeconomic pressures, combined with workforce challenges and extended government program timelines, create a particularly complex operating environment for small-cap companies like BioMark as we advance our diagnostic technologies and pursue strategic partnerships in domestic and international markets.

• BioMark’s strategic collaboration with Harrisburg University under the leadership of Dr. Maria Vaida, Assistant Professor of Data Science, along with Ph.D. student team created deep learning framework that maps biological signals from blood plasma using metabolite significantly enhance our assay performance and diagnostic capabilities. This productive partnership is yielding fruitful outcomes as we integrate cutting-edge artificial intelligence and dynamic machine learning approaches to advance our cancer diagnostic platform and pioneer new frontiers in metabolomics research.

• Later in June, Dr. Jean-François Haince, General Manager & Chief Scientific Officer, BioMark Diagnostic Solutions, joined the Quebec Delegation to the BIO International Convention, June 16-19, 2025, at Boston Convention & Exhibition Center. The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe. Through strategic networking and targeted engagement, Jeff had several promising meetings with various institutions across the US and Europe, positioning BioMark to explore business opportunities in key international markets. These initial discussions could open doors to potential partnerships, collaborative agreements, and market expansion opportunities that align with our strategic growth objectives. Jeff continues to actively pursue these business development leads, with formal follow-up meetings scheduled to advance these promising relationships. Further updates on the progression of these strategic opportunities will be provided as developments materialize.

• On June 26, 2025, the project titled “Development of Risk Prediction Model for Early Breast Cancer Detection” supported by NRC-IRAP program has been extended to one more month, all other terms and conditions remain unchanged.

• BioMark Diagnostic Solutions, the Company’s Quebec City subsidiary, has successfully completed a comprehensive hiring process for the Quality Assurance (QA) Director position. After conducting several rounds of interviews, BioMark has secured a seasoned QA lab director with extensive relevant experience specifically aligned with our certification and commercialization initiatives, as well as lab optimization objectives. This strategic hire, scheduled to commence on July 7, 2025, will be instrumental in guiding our centralized lab team toward achieving both accreditation and ISO certification milestones. The addition of this experienced QA professional directly supports our recent fundraising initiatives, as the use of proceeds was specifically earmarked for lab expansion and the addition of critical technical lab infrastructure. The Company continues to strategically expand its team to meet the growing staffing demands of both its commercial pipeline advancement and expanding R&D operations, ensuring that BioMark has the right expertise in place to execute our growth strategy effectively.

• BioMark is actively engaged in negotiations with leading third-party vendors to acquire state-of-the-art instrumentation for its laboratory facilities. This strategic expansion will significantly increase its analytical capabilities and processing capacity, positioning it to meet growing demand as it continues to establish high-value research and development collaborations with institutional partners across Europe and the USA. The enhanced laboratory infrastructure will enable accelerated sample throughput, improve assay precision, and support multiple concurrent projects – critical factors for scaling its operations and enhancing revenue generation through expanded collaborative partnerships. This instrumentation investment aligns directly with BioMark’s commercialization timeline and supports its ability to deliver on partnership commitments while maintaining the highest quality standards.

• BioMark continues to entertain discussions with various financial institutions, accredited individual investors, and government agencies to secure non-dilutive funding, favourable loans, and equity investments to accelerate the commercialization of its early lung cancer liquid biopsy franchise, to advance its expansion strategy in the USA and internationally as well as for general corporate purposes.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Not applicable.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Not applicable.

5. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements, etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Not applicable.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not applicable.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from, or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not applicable.

8. Describe the acquisition of new customers or loss of customers.

Not applicable.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists, and trademarks.

The Issuer continues to file trademarks and patents in specific jurisdictions for all its patents. Review of the filings and opinions from patent offices are being reviewed as needed.

10. Report on any employee hiring, terminations or lay-offs with details of the anticipated length of lay-offs.

Not applicable.

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not applicable.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Not applicable.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Not applicable.

14. Provide details of any securities issued and options or warrants granted.

Not applicable.

15. Provide details of any loans to or by Related Persons.

Not applicable.

16. Provide details of any changes in directors, officers, or committee members.

Not applicable.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are discussed in the Form 51-102F1 Management’s Discussion & Analysis Annual Report for the Year Ended March 31, 2024.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.

2. As of the date hereof there where is no material information concerning the Issuer which has not been publicly disclosed.

3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).

4. All of the information in this Form 7 Monthly Progress Report is true.

Dated July 3^rd, 2025